GIQuant provides an objective score for small bowel disease in children and adults. GIQuant analyses MRI data to produce a disease activity score based on small bowel motility. Use it to quickly identify cases where medications are ineffective and thereby optimise patient management.
GIQuant® integrates into existing abdominal MRI workflows to derive motion-related parameters, enabling quantitative assessment of small bowel motility (movement).
Output a GIQuant score
Measure the area of active disease and track changes in disease activity
Process historic patient MRI data
GDPR compliant: all patient data is processed on premises at the hospital. There is no cloud and no external data transfer
Requires motility MRI to produce a score along with an optimal set of acquisition parameters (i.e. 20 second breath hold)
Designed to work with your existing PACS infrastructure, including DICOM viewers and routine MRI protocols
Yes, as all patient data is processed on premises at the hospital. There is no cloud and no external data transfer.
No, GIQuant and its results are designed to work with your existing PACS infrastructure. We are able to connect with your system via existing trusted pathways, IEP for the UK and Powershare for North America, or dedicated gateways depending on your hospital IT's preference.
Yes, it is possible to process historic patient MRE scan data and extract GIQuant scores.
Read more at Menys A. et al. (2018). Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study. Radiology. 289(2):428‐435. doi:10.1148/radiol.2018180100
Yes. GIQuant requires motility MRI to produce a score along with an optimal set of image acquisition parameters (i.e. 20 second breath hold).
Intestinal motility is a relatively new parameter that looks at the physiology of the intestine (how it is moving) in a complementary way to the structure of the inestine (bowel wall thickening) as seen on T2.
It has the added benedit of not requiring IV contrast or a spasmolytic (e.g. Buscopan).
GIQuant has been designed to integrate seamlessly into existing routine workflows through the implementation of customisable configuration at installation.
Radiologist – GIQuant can be installed within your hospital PACS and the subject's data is auto-routed without you having to do anything. When GIQuant has finished, the derived data will be returned to that subjects session. Results may be annotated, and values quoted in a typical reporting process.
Gastroenterologist – During a consultation with a patient you would take into account the radiology report and the GIQuant score in comparing how the patient is responding to treatment. In some cases, it may be useful to access the results directly and talk the patient through their situation using the GIQuant results (and MRE in general) to help illustrate findings.
GIQuant has been designed and developed by Motilent to globally recognised medical device manufacturing standards. Motilent is ISO 13485 2016 certified.
Yes, GIQuant is only indicated for use with small bowel MRI data.
Generally, MRI shows high specificity and sensitivity for small bowel disease and this is why we have focused on this area in line with the optimal use case of the MRE test.
GIQuant has comparable performance to the widely accepted clinical trial endpoint MaRIA as well as a strong association with endoscopic (CDEIS) and histopathological (eAIS) measures of disease activity.
More can be read at:
Menys A. et al. (2018). Quantified Terminal Ileal Motility during MR Enterography as a Biomarker of Crohn Disease Activity: Prospective Multi-Institution Study. Radiology. 289(2):428‐435. doi:10.1148/radiol.2018180100
GIQuant is FDA Cleared (Class I) and CE Marked (Class Ila). It can be used for adults and children with routine MRE data.
Yes. GIQuant requires motility MRI to produce a score along with an optimal set of acquisition parameters (i.e. 20 second breath hold).
Intestinal motility is a relatively new parameter that looks at the physiology of the intestine (how it is moving) in a complementary way to the structure of the intestine (bowel wall thickening) as seen on T2.
It has the added benefit of not requiring IV contrast or a spasmolytic (e.g. Buscopan)
Find out more by reaching out to Motilent today. We aim to respond to you within 24hrs.